Structure and Function of Integrins in the Kidney
肾脏中整合素的结构和功能
基本信息
- 批准号:10375579
- 负责人:
- 金额:$ 62.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-06-01 至 2026-03-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAgonistAlbuminuriaAttenuatedBindingBiochemicalBloodCellsChemicalsChronicCilengitideComplexCryoelectron MicroscopyDataDevelopmentDiseaseDisease modelExperimental Animal ModelFVB MouseFiltrationFocal Segmental GlomerulosclerosisFoot ProcessGeneticGrantGrowth FactorHomeostasisHumanITGB3 geneImpairmentIn VitroInflammation MediatorsInflammatoryInjuryInsulin-Dependent Diabetes MellitusIntegrin alpha3Integrin alpha3beta1Integrin alphaVbeta3IntegrinsKidneyKidney DiseasesKnock-outLamininLaminin ReceptorLeadLigand BindingLigandsLipopolysaccharidesMaintenanceMechanicsModelingMolecular ConformationMorphologyMusMutationNonsense MutationPathogenesisPathologicPersonsPharmaceutical PreparationsPharmacologyPhysiologicalPlayProcessProteinsProteinuriaRattusRenal functionResistanceResolutionRodent ModelRoleSiteStimulusStructureTestingUrineVitronectinantagonistdiabeticextracellularglomerular basement membraneglomerular filtrationglomerular functioninhibitornovelosteopontinpodocytepreclinical studypressurepreventreceptorresponse to injuryshear stress
项目摘要
Abstract
The stoichiometric cis association of the tetraspanin CD151 with podocyte integrin α3β1 is essential for stabilizing
α3β1 in an active ligand-binding conformation, thus maintaining the integrity of the glomerular filtration barrier
(GFB). Other studies also show that activation of αvβ3 in podocytes by inflammatory mediators, growth factors
or mechanical/shear stress plays a critical role in disrupting the GFB. Taken together, these data suggest that
α3β1 and αvβ3 play opposing roles in regulating GFB homeostasis, but the biochemical and structural basis of
this functional antagonism in disease is unknown and how the glomerulus responds to injury in the complete
absence or inactivation of podocyte αvβ3 remains to be clarified. In preliminary studies, we show that αvβ3
ectodomain binds CD151 with similar EC50 to α3β1, that this interaction requires the active conformation of αvβ3
and is promoted by the αvβ3 inhibitors used in prior studies acting as partial agonists. These data lead us to
propose and test the hypothesis that activation of αvβ3 in disease states sequesters CD151 away from binding
to α3β1, thus impairing optimal α3β1 function and disrupting the GFB. In other preliminary studies, we
demonstrate the feasibility of obtaining a cryo-EM structure of an integrin in an inactive conformation in complex
with a tetraspanin, providing the feasibility for determining the structural basis of the active integrin conformation
that forms the complex with CD151. We have also generated mice with podocyte specific deletion of αv and
developed a novel class of αvβ3 inhibitors that are not partial agonists and that prevent rather than promote
αvβ3/CD151 association, which will also allow us to examine the glomerular response to injury when αvβ3 is
inactivated genetically or pharmacologically in rodent models of proteinuric kidney disease.
摘要
四跨膜蛋白CD 151与足细胞整合素α3β1的化学计量顺式缔合对于稳定
α3β1处于活性配体结合构象,从而维持肾小球滤过屏障的完整性
(GFB)。其他研究也表明,足细胞中的αvβ3被炎症介质、生长因子
或机械/剪切应力在破坏GFB中起关键作用。综合来看,这些数据表明,
α3β1和αvβ3在调节GFB内稳态中起相反的作用,但GFB内稳态的生化和结构基础,
疾病中的这种功能性拮抗作用尚不清楚,肾小球如何对损伤作出反应,
足细胞αvβ3的缺失或失活仍有待澄清。在初步研究中,我们表明αvβ3
胞外域以与α3β1相似的EC 50结合CD 151,这种相互作用需要αvβ3的活性构象
并且通过在先前研究中用作部分激动剂的αvβ3抑制剂来促进。这些数据使我们
提出并检验了一个假设,即在疾病状态下αvβ3的激活会使CD 151与CD 151分离,
转化为α3β1,从而损害最佳α3β1功能并破坏GFB。在其他初步研究中,我们
证明了在复合物中获得无活性构象的整合素的冷冻-EM结构的可行性
与四跨膜蛋白,提供了确定活性整合素构象的结构基础的可行性
与CD 151形成复合物。我们还产生了足细胞特异性缺失αv的小鼠,
开发了一类新型αvβ3抑制剂,不是部分激动剂,
αvβ3/CD 151的相关性,这也将使我们能够检查当αvβ3被抑制时肾小球对损伤的反应。
在啮齿类动物蛋白尿肾病模型中,
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(4)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
M. AMIN ARNAOUT其他文献
M. AMIN ARNAOUT的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('M. AMIN ARNAOUT', 18)}}的其他基金
Targeting innate immunity for induction of robust renal allograft tolerance
针对先天免疫诱导强大的肾同种异体移植耐受
- 批准号:
10622050 - 财政年份:2023
- 资助金额:
$ 62.7万 - 项目类别:
Effects of combining anti-CD40 and anti-CD11b mAb107 on survival of pig kidney xenografts in cynomolgus monkeys
抗CD40和抗CD11b mAb107联合使用对食蟹猴猪肾异种移植物存活的影响
- 批准号:
10425736 - 财政年份:2022
- 资助金额:
$ 62.7万 - 项目类别:
Effects of combining anti-CD40 and anti-CD11b mAb107 on survival of pig kidney xenografts in cynomolgus monkeys
抗CD40和抗CD11b mAb107联合使用对食蟹猴猪肾异种移植物存活的影响
- 批准号:
10618872 - 财政年份:2022
- 资助金额:
$ 62.7万 - 项目类别:
Platelet alphaIIbbeta3 activation and its therapeutic targeting
血小板αIIbbeta3激活及其治疗靶向
- 批准号:
10469477 - 财政年份:2019
- 资助金额:
$ 62.7万 - 项目类别:
Platelet alphaIIbbeta3 activation and its therapeutic targeting
血小板αIIbbeta3激活及其治疗靶向
- 批准号:
10251142 - 财政年份:2019
- 资助金额:
$ 62.7万 - 项目类别:
Platelet alphaIIbbeta3 activation and its therapeutic targeting
血小板αIIbbeta3激活及其治疗靶向
- 批准号:
10004711 - 财政年份:2019
- 资助金额:
$ 62.7万 - 项目类别:
Role of integrin CD11b in delayed graft function and allorejection
整合素 CD11b 在移植物功能延迟和同种异体排斥中的作用
- 批准号:
9809349 - 财政年份:2019
- 资助金额:
$ 62.7万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 62.7万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 62.7万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 62.7万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 62.7万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 62.7万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 62.7万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 62.7万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 62.7万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 62.7万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 62.7万 - 项目类别: